Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
Focuses on therapeutic targets identified after TNF blockade and that have recently been registered or are currently under development
Discusses the biological rationale of all therapeutic targets in great detail, including results from clinical trials
Features an international team of expert authors
The volume focuses on therapeutic targets that were identified after TNF blockade and that have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter discusses the biological rationale in great detail, including in vitro work and work in animal models, and where appropriate, results from clinical trials.
The book is written by an international authorship of experts in this field. It is of interest to rheumatologists, immunologists, internists, investigators in immunology and rheumatology as well as the pharmaceutical industry.
B cell targets in rheumatoid arthritis.- Co-stimulatory pathways in the therapy of rheumatoid arthritis.- Immunobiology of IL-6 - Tocilizumab (Humanized anti-IL-6 receptor antibody ) for the treatment of RA.- Role of IL-1 in erosive arthritis, lessons from animal models.- Interleukin-15.- IL-17 and Th17 cells, key players in arthritis.- Role of il-18 in inflammatory diseases.- Chemokines and chemokine receptors.- Signaling pathways in rheumatoid arthritis.- Targeting oncostatin M in the treatment of rheumatoid arthritis.- Targeting the epigenetic modifications of synovial cells.- Perspectives in targeted therapy.